Digestive adaptation with intestinal reserve: A neuroendocrine-based operation for morbid obesity

Obesity Surgery

Volumn 16, Issue 10, 2006, Pages 1371-1379

  Santoro, Sérgio ^a,d   Malzoni, Carlos E ^a   Velhote, Manoel C P ^b   Milleo, Fábio Q ^c   Santo, Marco A ^b   Klajner, Sidney ^a   Damiani, Durval ^b   Maksoud, João G ^b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Hospital Vicentino da Sociedade Beneficente São Camilo   (Brazil)

^d Hospital das Clínicas ^*  (Brazil)

Author keywords

Enterectomy; Gastrectomy; Ghrelin; GLP 1; Morbid obesity; Obesity; Omentectomy; PAI 1; PYY; Resistin; Visceral fat

Indexed keywords

GHRELIN; PEPTIDE YY; RESISTIN;

ADULT; ARTICLE; BODY MASS; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; GASTRECTOMY; HUMAN; HYPERTENSION; INTESTINE ANASTOMOSIS; INTESTINE RESECTION; MAJOR CLINICAL STUDY; MALE; MORBID OBESITY; PRIORITY JOURNAL; RADIOGRAPHY;

EID: 33750537234     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1381/096089206778663841     Document Type: Article

References (34)

1. Castillo J, Fabrega E, Escalante CF et al. Liver transplantation in a case of steatohepatitis and subacute hepatic failure after biliopancreatic diversion for morbid obesity. Obes Surg 2001; 11: 640-2.
2. Baltasar A, Serra C, Perez N et al. Clinical hepatic impairment after duodenal switch. Obes Surg 2004; 14: 77-83.
3. Beymer, C, Kowdley K, Larson A et al. Prevalence and predictors of asymptomatic liver disease in patients undergoing gastric bypass surgery. Arch Surg 2003; 138: 1240-4.
4. Cotler SJ, Vitello JM, Guzman G et al. Hepatic decompensation after gastric bypass surgery for severe obesity. Dig Dis Sci 2004; 49: 1563-8.
5. Santoro S, Velhote MC, Malzoni CE et al. Digestive adaptation with intestinal reserve: A new surgical proposal for morbid obesity. Rev Bras Videocir 2004; 2: 130-8. Available at http://www.sobracil.org.br/
6. 3-36. N Eng J Med 2003; 349: 941-8.
7. Ranganath LR, Beety JM, Morgan LM et al. Attenuated GLP-1 secretion in obesity: cause or consequence? Gut 1996; 38: 916-9.
8. Lugari R, Dei Cas A, Ugolotti D et al. Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res 2002; 34: 150-4.
9. Santoro S. Relações entre o comprimento do intestino e a obesidade. Hipótese: a Síndrome do Intestino Longo. Einstein 2003; 1(1) 63-4. Available at http://www.einstein.br/biblioteca/
10. Patriti A, Facchiano E, Sanna A et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14: 840-8.
11. Egan JM, Meneilly GS, Habener JF et al. Glucagon-like Peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab 2002; 87: 3768-73.
12. Layer P, Holst JJ, Grandt D et al. Heal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40: 1074-82.
13. Nauck MA, Niedereichholz U, Ettler R et al. Glucagon-like peptide l inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 1997; 273 (5 Pt 1): E981-8.
14. Schirra J, Wank U, Arnold R et al. Effects of glucagon-like peptide-1(7-36) amide on motility and sensation of the proximal stomach in humans. Gut 2002; 50: 341-8.
15. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18: 7-14.
16. Dumont Y, Fournier A, St-Pierre S et al. Characterization of neuropeptide Y binding sites in rat brain membrane preparations using [125I][Leu31,Pro34] peptide YY and [125I] peptide YY3-36 as selective Y1 and Y2 radioligands. J Pharmacol Exp Ther 1995; 272: 673-80.
17. Ballantyne GH. Peptide YY(1-36) and Peptide YY(3-36): Part I: Distribution, release and actions. Obes Surg 2006; 16: 651-8.
18. Cohen MA, Ellis SM, Le Roux C et al. Oxyntomodulin suppresses appetite and reduces food intake in jumans. J Clin Endocrinol Metab 2003; 88: 4696-701.
19. Naslund E, Gryback P, Hellstrom PM et al. Gastrointestinal hormones and gastric emptying 20 years after jejuno ileal bypass for massive obesity. Int J Obes 1997; 48: 387-92.
20. Bray GA The underlying basis for obesity: relationship to cancer. J Nutr 2002; 132 (Suppl 11): 3451S-3455S.
21. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17: 161-71.
22. Dolara P, Caderni G, Salvadori M et al. Fecal levels of short-chain fatty acids and bile acids as determinants of colonic mucosal cell proliferation in humans. Nutr Cancer 2002; 42: 186-90.
23. Hounnou G, Destrieux C, Desme J et al. Anatomical study of the length of the human intestine. Surg Radiol Anat 2002; 24: 290-4.
24. Aiello LC, Wheeler P. The expensive tissue hypothesis: The brain and the digestive system in human and primate evolution. Curr Anthropol 1995; 36: 199-221.
25. Leonard WR, Robertson ML. Evolutionary perspectives on human nutrition: The influence of brain and body size on diet and metabolism. Am J Hum Biol 1994; 6: 77-88.
26. Stevens CE, Hume ID. Comparative Physiology of the Vertebrate Digestive System. Cambridge, United Kingdom: Cambridge University Press, 1995.
27. Santoro S, Velhote MCP, Malzoni CE et al. Digestive Adaptation: A new surgical proposal to treat obesity based in physiology and eevolution. Einstein 2003; 1(2): 99-104. Available at http://www.einstein.br/biblioteca/
28. Langer FB, Reza Hoda MA, Bohdjalian A et al. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg 2005; 15: 1024-9.
29. Santoro S, Velhote MCP, Malzoni CE et al. Preliminary results of digestive adaptation: a new surgical proposal to treat obesity based in physiology and evolution. São Paulo Med J 2006; 124(4): 192-7.
30. Layer P, Holst JJ, Grandt D et al. Heal release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 1995; 40: 1074-82.
31. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000; 32 (Suppl 1): 78-84.
32. McTernan CL, McTernan PG, Harte AL et al. Resistin, central obesity, and type 2 diabetes. Lancet 2002; 359 (9300): 46-7.
33. Storlien LH, Kriketos AD, Calvert GD et al. Fatty acids, triglycerides and syndromes of insulin resistance. Prostaglandins Leukot Essent Fatty Acids. 1997; 57: 379-85.
34. Stankevicius E, Kevelaitis E, Vainorius E et al. Role of nitric oxide and other endothelium-derived factors. Medicina 2003; 39: 3-41.